| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
platelet-activating factor[1]
Platelet-activating factor receptor (PAFR). Homoeriodictyol 7-O-β-D-glucoside is a natural antagonist of platelet-activating factor (PAF). By binding to the PAF receptor, it inhibits PAF-induced platelet aggregation. It shows selectivity for PAF-induced aggregation over ADP-induced aggregation. Its antagonistic activity has been demonstrated in both human and rabbit platelet models. |
|---|---|
| ln Vitro |
Homoeriodictyol 7-O-β-D-glucoside strongly suppresses human and rabbit platelet aggregation induced by PAF, but has no inhibitory impact on platelet aggregation induced by Adenosine diphosphate (ADP)[1].
Homoeriodictyol 7-O-β-D-glucoside inhibits human and rabbit platelet aggregation induced by PAF, with an IC50 of 0.8 μM. It has no inhibitory effect on platelet aggregation induced by adenosine diphosphate (ADP). This selectivity for PAF-induced aggregation makes it a useful tool for studying PAF-mediated signaling in platelet function and inflammatory responses. |
| ln Vivo |
In vivo, Homoeriodictyol 7-O-β-D-glucoside would be expected to exert anti-inflammatory and anti-thrombotic effects through its PAF antagonistic activity. By blocking PAF-mediated platelet aggregation and inflammatory signaling, it may have potential for studying cardiovascular and inflammatory diseases. Its natural origin and selectivity make it an interesting candidate for further in vivo investigation.
|
| Enzyme Assay |
In vitro receptor binding assays are used to characterize Homoeriodictyol 7-O-β-D-glucoside as a PAF receptor antagonist. Typically, radioligand binding assays are performed using platelets or cells expressing the PAF receptor, and the compound's ability to displace a labeled PAF ligand is measured to determine its binding affinity and confirm its antagonistic activity.
|
| Cell Assay |
Cellular assays for Homoeriodictyol 7-O-β-D-glucoside involve treating human or rabbit platelets with the compound and then stimulating with PAF. Platelet aggregation is measured as a readout of PAF receptor activation. The compound inhibits PAF-induced aggregation with an IC50 of 0.8 μM, while showing no effect on ADP-induced aggregation.
|
| Animal Protocol |
In vivo studies with Homoeriodictyol 7-O-β-D-glucoside would be performed in animal models of thrombosis or inflammation. The compound could be administered orally or via injection, and its effects on platelet aggregation, thrombus formation, and inflammatory responses would be assessed. Its PAF antagonistic activity makes it a potential tool for studying PAF-mediated diseases.
|
| ADME/Pharmacokinetics |
Homoeriodictyol 7-O-β-D-glucoside has a molecular formula of C22H24O11 and a molecular weight of 464.42. As a natural flavonoid glycoside, its pharmacokinetic properties would be characteristic of this class, with potential for oral bioavailability and metabolism in the gut and liver. The compound should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for Homoeriodictyol 7-O-β-D-glucoside. As a naturally occurring flavonoid glycoside, it is generally considered to have low toxicity. Standard toxicity assessments would include evaluation of cytotoxicity and safety in animal models. The compound is for research use only and not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
According to reports, Viscum articulatum, Viscum coloratum, and Limium aureum contain high-oxalate 7-O-glucoside, and there is available data.
Homoeriodictyol 7-O-β-D-glucoside (CAS#: 14982-11-7) is a natural platelet-activating factor (PAF) antagonist isolated from Viscum coloratum. It has a molecular formula of C22H24O11 and a molecular weight of 464.42. The compound inhibits PAF-induced human and rabbit platelet aggregation with an IC50 of 0.8 μM, with no effect on ADP-induced aggregation. It is a research tool for studying PAF-mediated inflammation and thrombosis. |
| Molecular Formula |
C22H24O11
|
|---|---|
| Molecular Weight |
464.42
|
| Exact Mass |
464.132
|
| CAS # |
14982-11-7
|
| PubChem CID |
21629877
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
0.6
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
677
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
O1[C@H]([C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O)OC1C=C(C2C(C[C@@H](C3C=CC(=C(C=3)OC)O)OC=2C=1)=O)O
|
| InChi Key |
KZQCCKUDYVSOLC-YMTXFHFDSA-N
|
| InChi Code |
InChI=1S/C22H24O11/c1-30-15-4-9(2-3-11(15)24)14-7-13(26)18-12(25)5-10(6-16(18)32-14)31-22-21(29)20(28)19(27)17(8-23)33-22/h2-6,14,17,19-25,27-29H,7-8H2,1H3/t14-,17+,19+,20-,21+,22+/m0/s1
|
| Chemical Name |
(2S)-5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1532 mL | 10.7661 mL | 21.5322 mL | |
| 5 mM | 0.4306 mL | 2.1532 mL | 4.3064 mL | |
| 10 mM | 0.2153 mL | 1.0766 mL | 2.1532 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
